Latest Options News

Coles Group Limited has announced a fully franked ordinary dividend of AUD 0.32 per share for the fiscal year ending June 2025, with a Dividend Reinvestment Plan available to shareholders.

Aurelia Metals delivered a robust FY25 with a $48.9 million net profit and strong operational execution, advancing key projects like Federation and Great Cobar while maintaining a solid balance sheet.

Premier1 Lithium has announced its first inferred mineral resource at the Wadgingarra gold project, marking a significant step towards commercial gold production with promising expansion potential.

Mader Group Limited has reported a solid 13% increase in both revenue and profit for the 2025 financial year, accompanied by a notable rise in dividends.

Fortescue Ltd has announced a fully franked ordinary dividend of AUD 0.60 per share for the fiscal year ending June 30, 2025, with a dividend reinvestment plan available to shareholders.

Noumi Limited reported modest revenue growth and a significant rise in adjusted EBITDA for FY25, driven by its Milklab brand’s strong performance and a continued turnaround in its Dairy & Nutritionals segment. The company also resolved all legacy legal issues, positioning itself for future growth.

Askari Metals is gearing up for a pivotal shareholder meeting to approve its Ethiopian gold and copper acquisition, while restructuring debt and expanding European investor outreach.

Firebrick Pharma has closed a $1.4 million placement to fund expansion of its Nasodine nasal spray in key international markets and advance new product development.

Firebrick Pharma has secured an exclusive licensing agreement with Innorini Pte Ltd to distribute Nasodine products across Singapore, Malaysia, Brunei, and Mauritius, aiming to reduce marketing expenses and broaden market access.

Ora Banda Mining Ltd delivered a standout FY25 with net profit soaring 575% to $186 million, driven by record gold production and successful underground mine expansions. The company sets ambitious FY26 targets amid strong operational momentum.

Veris Limited has reported a significant turnaround in FY25, posting a $2 million profit before tax on $97.2 million revenue, driven by growth in digital and spatial advisory services and strategic acquisitions.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.